J
Joel M. Reid
Researcher at Mayo Clinic
Publications - 274
Citations - 11448
Joel M. Reid is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Pharmacokinetics & Medicine. The author has an hindex of 50, co-authored 248 publications receiving 10094 citations. Previous affiliations of Joel M. Reid include Oregon Health & Science University & Upjohn.
Papers
More filters
Journal ArticleDOI
A phase I trial of the combination of erlotinib and tipifarnib in patients with advanced solid tumors
Cynthia X. Ma,Gary A. Croghan,Joel M. Reid,Lorelei J. Hanson,Sumithra J. Mandrekar,Randolph S. Marks,Araba A. Adjei,Alfred Furth +7 more
TL;DR: The goal of this phase I study was to determine the maximum tolerated dose (MTD), pharmacokinetics (PK), and pharmacodynamics of erlotinib in combination with tipifarnib.
Journal ArticleDOI
Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside.
TL;DR: Z-endoxifen, a secondary metabolite resulting from CYP2D6-dependent biotransformation of the primary tamioxifen metabolite, is the only endocrine agent with FDA approval for both the prevention and treatment of premenopausal and postmenopausal estrogen-receptor positive breast cancer as well as for the treatment of male breast cancer.
Journal ArticleDOI
A phase Ib trial of CB-839 (telaglenastat) in combination with radiation therapy and temozolomide in patients with IDH-mutated diffuse astrocytoma and anaplastic astrocytoma (NCT03528642).
Sani H. Kizilbash,Samuel K. McBrayer,John D. Port,Joel M. Reid,Ian R. Lanza,Jacob B. Allred,Arnab Chakravarti,Charles A. Kunos,Alex A. Adjei +8 more
TL;DR: IDH mutant astrocytomas express high levels of 2-hydroxyglutarate, an oncogenic metabolite which drives gliomagenesis, which inhibits branched chain amino acid trans...
Journal ArticleDOI
Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2.
Tanda M. Dudenkov,Duan Liu,Junmei Cairns,Sandhya Devarajan,Yongxian Zhuang,James N. Ingle,Aman U. Buzdar,Mark E. Robson,Michiaki Kubo,Anthony Batzler,Poulami Barman,Gregory D. Jenkins,Erin E. Carlson,Matthew P. Goetz,Donald W. Northfelt,Alvaro Moreno-Aspitia,Zeruesenay Desta,Joel M. Reid,Krishna R. Kalari,Liewei Wang,Richard M. Weinshilboum +20 more
TL;DR: A novel gene encoding an anastrozole transporter, SLC38A7, was identified, as well as epistatic interaction between SNPs in that gene and SNPs near ALPPL2 that influenced both the expression of the transporter and anast rozole plasma concentrations.
Journal ArticleDOI
A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN).
Andrew Bukowinski,Bill H. Chang,Joel M. Reid,Xiaowei Liu,Charles G. Minard,Jane B. Trepel,Min-Jung Lee,Elizabeth Fox,Brenda J. Weigel +8 more
TL;DR: In this paper, a phase I trial was conducted to determine the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D), toxicity profile, pharmacokinetics (PK), and pharmacodynamics (PD) of entinostat in children with relapsed or refractory solid tumors including central nervous system (CNS) malignancies.